Neurotech Narrows Half-Year Loss as Revenue Doubles

The latest update is out from Neurotech International ( (AU:NTI) ).

Neurotech International reported a 100% increase in revenue from ordinary activities to $4.7 million for the half year to 31 December 2025, while its net loss attributable to owners narrowed sharply to $697,000, down 91% from the prior corresponding period. The improved result reflects a substantial reduction in losses despite ongoing research and development spending of $4.2 million, indicating tighter cost control and a gradual strengthening of the company’s financial position, although no dividends were declared and net tangible assets edged down to 0.5 cents per share.

The group’s loss after tax came in at $696,501 compared with $7.4 million a year earlier, underscoring the impact of disciplined spending alongside rising revenue from operations. With the interim financial statements reviewed by BDO Audit Pty Ltd, the company signals operational progress but also highlights that it remains in an investment phase, prioritising R&D over shareholder distributions for now.

The most recent analyst rating on (AU:NTI) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Neurotech International stock, see the AU:NTI Stock Forecast page.

More about Neurotech International

Neurotech International Limited is an Australian company focused on developing medical technologies, with a strong emphasis on research and development in its core therapeutic areas. The business continues to invest heavily in R&D, which remains a major component of its operating expenditure and a key driver of its long-term growth strategy.

Average Trading Volume: 1,372,876

Technical Sentiment Signal: Sell

Current Market Cap: A$16.85M

Find detailed analytics on NTI stock on TipRanks’ Stock Analysis page.